Dmitry Balyasny’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Dmitry Balyasny’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-297,182	Closed	-$39.1M	–	2251
2020 Q4	$39.1M	Buy	+297,182	New	+$26.3M	0.22%	111
2018 Q4	–	Sell	-32,095	Closed	-$320K	–	1909
2018 Q3	$320K	Sell	32,095 -48,505	-60%	-$797K	﹤0.01%	1489
2018 Q2	$1.64M	Buy	+80,600	New	+$1.69M	0.01%	997

Dmitry Balyasny's EIDX Position: Q1 2021 in Review

Dmitry Balyasny sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 297,182 shares — an estimated $39.1M sold.

Dmitry Balyasny first reported a position in EIDX in Q2 2018 and held it in 3 quarters. The position peaked at $39.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Dmitry Balyasny reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Dmitry Balyasny sold 297,182 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $39.1M.
Dmitry Balyasny first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
Dmitry Balyasny's Eidos Therapeutics, Inc. Common Stock position peaked at $39.1M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Balyasny Asset Management's 13F filing for Q1 2021, filed 17 May 2021.